Claims
- 1. A compound of Formula I:
- 2. A compound according to claim 1 of formula:
- 3. A compound according to claim 2 of formula:
- 4. A compound according to claim 3 of formula
- 5. A compound according to claim 1 of formula
- 6. A compound according to claim 1 wherein R4 is C7 to C24 alkyl.
- 7. A compound according to claim 1 of formula:
- 8. A compound according to claim 7 of formula:
- 9. A compound according to claim 8 of formula
- 10. A compound according to claim 7 of formula
- 11. A compound according to claim 7 wherein R5 is hydrogen or lower alkyl.
- 12. A compound according to claim 7 wherein R6 is C7 to C24 alkyl.
- 13. A compound according to claim 3 of formula
- 14. A method for treating bronchospasm comprising administering a compound of claim 1.
- 15. A method for inducing bronchodilation comprising administering a compound of claim 1.
- 16. A method for treating inflammatory conditions comprising administering a compound of claim 1.
- 17. A method according to claim 16 wherein said inflammatory condition is chronic obstructive pulmonary disease.
- 18. A method according to claim 16 wherein said inflammatory condition is asthma.
- 19. A method according to claim 16 wherein said inflammatory condition is rhinitis.
- 20. A method according to claim 16 wherein said compound is administered by inhalation.
- 21. A method for treating a disorder chosen from osteoarthritis, bursitis, epicondylitis, tenosynovitis, lichen simplex chronicus, granuloma annulare, lichen planus, keloids, alopecia areata, discoid lupus erythematosus, localised neurodermatitis, cystic acne, granuloma annulare, nummular and dyshydrotic eczema, hypertrophic scars and macular degeneration comprising administering the compound of claim 1.
- 22. A pharmaceutical formulation for inhalation comprising a compound according to claim 1 and a pharmaceutically acceptable fluid for suspension or solution.
- 23. A pharmaceutical formulation for topical application comprising a compound according to claim 1 and a pharmaceutically acceptable carrier for topical or transdermal application.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the priorities of U.S. provisional applications No. 60/358,246, filed Feb. 20, 2002, and No. 60/428,180, filed Nov. 21, 2002. The entire disclosures of both are incorporated herein by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60358246 |
Feb 2002 |
US |
|
60428180 |
Nov 2002 |
US |